

**Food and Drug Administration, HHS**

**§ 5.1100**

(b) Within 60 days of the filing date of a request for designation, the product jurisdiction officer will issue a letter of designation to the sponsor, with copies to the centers, specifying the agency component designated to have primary jurisdiction for the premarket review and regulation of the product at issue, and any consulting agency components. The product jurisdiction officer may request a meeting with the sponsor during the review period to discuss the request for designation. If the product jurisdiction officer has not issued a letter of designation within 60 days of the filing date of a request for designation, the sponsor's recommendation of the center with primary jurisdiction, in accordance with §3.7(c)(3), shall become the designated agency component.

(c) Request for reconsideration by sponsor: If the sponsor disagrees with the designation, it may request the product jurisdiction officer to reconsider the decision by filing, within 15 days of receipt of the letter of designation, a written request for reconsideration not exceeding 5 pages. No new information may be included in a request for reconsideration. The product jurisdiction officer shall review and act on the request in writing within 15 days of its receipt.

**§ 3.9 Effect of letter of designation.**

(a) The letter of designation constitutes an agency determination that is subject to change only as provided in paragraph (b) of this section.

(b) The product jurisdiction officer may change the designated agency component with the written consent of the sponsor, or without its consent to protect the public health or for other compelling reasons. A sponsor shall be given 30 days written notice of any proposed nonconsensual change in designated agency component. The sponsor may request an additional 30 days to submit written objections, not to exceed 15 pages, to the proposed change, and shall be granted, upon request, a timely meeting with the product jurisdiction officer and appropriate center officials. Within 30 days of receipt of the sponsor's written objections, the product jurisdiction officer shall issue to the sponsor, with copies to appro-

appropriate center officials, a written determination setting forth a statement of reasons for the proposed change in designated agency component. A non-consensual change in the designated agency component requires the concurrence of the Principal Associate Commissioner.

[56 FR 58756, Nov. 21, 1991, as amended at 68 FR 37077, June 23, 2003]

**§ 3.10 Stay of review time.**

Any filing with or review by the product jurisdiction officer stays the review clock or other established time periods for agency action for an application for marketing approval or required investigational notice during the pendency of the review by the product jurisdiction officer.

**Subpart B [Reserved]**

**PART 5—ORGANIZATION**

**Subparts A–L [Reserved]**

**Subpart M—Organization**

Sec.

5.1100 Headquarters.

5.1105 Chief Counsel, Food and Drug Administration.

5.1110 FDA Public Information Offices.

5.1115 Field structure.

AUTHORITY: 5 U.S.C. 552; 21 U.S.C. 301–397.

SOURCE: 69 FR 17286, Apr. 2, 2004, unless otherwise noted.

**Subparts A–L [Reserved]**

**Subpart M—Organization**

**§ 5.1100 Headquarters.**

The central organization of the Food and Drug Administration consists of the following:

OFFICE OF THE COMMISSIONER.<sup>1</sup>

*Office of the Chief Counsel.*<sup>2</sup>

<sup>1</sup>Mailing address: 5600 Fishers Lane, Rockville, MD 20857.

<sup>2</sup>The Office of the Chief Counsel (also known as the Food and Drug Division, Office of the General Counsel, Department of

*Continued*